Latest News

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.
Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs

January 29th 2025

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.

T-DM1 Shows Promise in HER2+ Biliary Tract Cancer
T-DM1 Shows Promise in HER2+ Biliary Tract Cancer

January 28th 2025

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.
Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC

January 27th 2025

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.
Fruquintinib Combo Shows Activity in Pretreated Metastatic CRC

January 27th 2025

Pembrolizumab plus lenvatinib showed a safety profile consistent with previous reports evaluating the combination.
Pembrolizumab Combo Does Not Meet OS End Point in Advanced Gastric Cancer

January 27th 2025